<DOC>
	<DOCNO>NCT00786422</DOCNO>
	<brief_summary>This multicenter , cohort study evaluate adapt rivaroxaban dose regimen patient acute , proximal deep-vein thrombosis ( DVT ) acute pulmonary embolism ( PE ) concomitantly use strong cytochrome P450 isoenzyme 3A4 ( CYP 3A4 ) inducer entire 3-month study duration .</brief_summary>
	<brief_title>Deep Vein Thrombosis Treatment With Oral Direct Factor Xa Inhibitor Rivaroxaban Patients Using Strong CYP 3A4 Inducer</brief_title>
	<detailed_description>The following laboratory variable determine baseline local laboratory : Hemoglobin , platelet , activate partial thromboplastin time ( aPTT ) , international normalize ratio ( INR ) , alanine aminotransferase ( ALT ) , creatinine .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inducers</mesh_term>
	<criteria>Confirmed acute symptomatic proximal deep vein thrombosis and/or pulmonary embolism Concomitant use strong CYP 3A4 inducer , ( i.e. , carbamazepine , phenytoin , rifampicin/rifampin , rifabutin ) Legal low age limitation ( country specific ) Thrombectomy , insertion caval filter , use fibrinolytic agent treat current episode deep vein thrombosis and/or pulmonary embolism Other indication vitamin K antagonist ( VKA ) deep vein thrombosis and/or pulmonary embolism Concomitant use strong CYP3A4 inhibitor ( e.g. , HIV protease inhibitor , systemic ketoconazole ) Use strong CYP 3A4 inducer phenobarbital/primidone St John 's Wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Embolism Thrombosis</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Embolism</keyword>
	<keyword>Venous Thrombosis</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Enzyme Inducers</keyword>
	<keyword>CYP Inducers</keyword>
	<keyword>Cohort Study</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Human Immunodeficiency Virus ( HIV )</keyword>
	<keyword>Neurologic disease</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Fibrin Modulating Agents</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Cardiovascular Agents</keyword>
</DOC>